- Trials with a EudraCT protocol (96)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
96 result(s) found for: Nivolumab and NSCLC.
Displaying page 4 of 5.
EudraCT Number: 2018-001400-11 | Sponsor Protocol Number: 20170543 | Start Date*: 2019-11-14 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mu... | ||||||||||||||||||
Medical condition: KRAS p.G12C mutant advanced NSCLC, CRC, and other solid tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) AT (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) ES (Temporarily Halted) HU (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003732-20 | Sponsor Protocol Number: GECP16/03 | Start Date*: 2017-01-24 |
Sponsor Name:Grupo Español de Cáncer de Pulmón | ||
Full Title: NEO -ADJUVANT CHEMO/IMMUNOTHERAPY FOR THE TREATMENT OF RESECTABLE STAGE IIIA NON SMALL CELL LUNG CANCER (NSCLC): A PHASE II MULTICENTER EXPLORATORY STUD | ||
Medical condition: Non small cell lung cáncer limited stage IIIA | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2020-005016-21 | Sponsor Protocol Number: FW-2020-1 | Start Date*: 2021-11-15 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Famewave Ltd. | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumours | ||||||||||||||||||||||||||||||||||||||
Medical condition: Part A- Recurrent and metastatic non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and melanoma Part B- Recurrent or metasta... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004548-12 | Sponsor Protocol Number: RPL-001-16 | Start Date*: 2017-08-30 | |||||||||||
Sponsor Name:Replimune Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors [IGNYTE] | |||||||||||||
Medical condition: Advanced solid tumours | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004194-95 | Sponsor Protocol Number: CC-90011-ST-002 | Start Date*: 2020-04-09 | |||||||||||||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||||||||||||
Full Title: A Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with advanced cancers. | |||||||||||||||||||||||
Medical condition: Small cell lung cancer (SCLC) and squamous non-small cell lung cancer (sqNSCLC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001063-36 | Sponsor Protocol Number: eNERGY | Start Date*: 2016-06-16 | |||||||||||
Sponsor Name:CHU Rennes | |||||||||||||
Full Title: Randomised phase III study testing nivolumab versus chemotherapy in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer | |||||||||||||
Medical condition: Advanced non small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002842-60 | Sponsor Protocol Number: eNERGY | Start Date*: 2017-09-14 | |||||||||||
Sponsor Name:CHU Rennes | |||||||||||||
Full Title: Randomised phase III study testing nivolumab and ipilimumab versus a carboplatin based doublet in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small... | |||||||||||||
Medical condition: Advanced non small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000163-53 | Sponsor Protocol Number: EV-2101 | Start Date*: 2022-05-25 | ||||||||||||||||
Sponsor Name:EverImmune SAS | ||||||||||||||||||
Full Title: A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS | ||||||||||||||||||
Medical condition: Metastatic Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001385-35 | Sponsor Protocol Number: EXS21546-002 | Start Date*: 2022-11-25 | ||||||||||||||||
Sponsor Name:Exscientia AI Limited | ||||||||||||||||||
Full Title: A phase 1b/2a study to assess the safety, tolerability, pharmacokinetic and anti-tumoural activity of EXS21546 in combination with PD-1 inhibitor in patients with advanced solid tumours. | ||||||||||||||||||
Medical condition: Solid advanced tumours | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001097-29 | Sponsor Protocol Number: CA209-7T4 | Start Date*: 2020-07-27 | |||||||||||
Sponsor Name:Amsterdam UMC, VU University Medical Center | |||||||||||||
Full Title: Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients, a proof-of-concept study. | |||||||||||||
Medical condition: advanced non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003653-29 | Sponsor Protocol Number: BT5528-100 | Start Date*: 2020-10-09 | |||||||||||
Sponsor Name:Bicycle Tx Limited | |||||||||||||
Full Title: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression | |||||||||||||
Medical condition: Advanced Malignancies Associated with EphA2 Expression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002719-23 | Sponsor Protocol Number: BT8009-100 | Start Date*: 2020-10-29 | |||||||||||
Sponsor Name:BicycleTx Ltd. | |||||||||||||
Full Title: BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies | |||||||||||||
Medical condition: Nectin-4 Expressing Advanced Malignancies. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003947-39 | Sponsor Protocol Number: GECP17/02 | Start Date*: 2018-06-05 | |||||||||||
Sponsor Name:Spanish Long Cancer Group (SLCG/GECP) | |||||||||||||
Full Title: A Phase II open-label multicenter exploratory study to assess efficacy of Pembrolizumab re-challange as second or further line in patients with advanced non - small cell lung cancer | |||||||||||||
Medical condition: Pembrolizumab re-challange as second or further line in patients with advanced non - small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002313-41 | Sponsor Protocol Number: CRC2021-02 | Start Date*: 2023-06-06 | ||||||||||||||||
Sponsor Name:CENTRO RICERCHE CLINICHE DI VERONA | ||||||||||||||||||
Full Title: A PHASE 2, MULTICENTER, OPEN LABEL, CLINICAL TRIAL EVALUATING SAFETY AND ACTIVITY OF NIVOLUMAB/IPILIMUMAB AND CHEMOTHERAPY COMBINATION IN ADVANCED NSCLC PATIENTS WITH HIV, HBV, HCV AND POST-ACUTE S... | ||||||||||||||||||
Medical condition: advanced non-small-cell lung cancer (NSCLC) (both squamous and non-squamous) in patients with chronic viral infections or sequalae from Sars-Cov2 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003965-16 | Sponsor Protocol Number: CA209-063 | Start Date*: 2013-05-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Single-Arm Phase 2 Study of BMS-936558 in Subjects with Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens (CheckMate 063: CHE... | |||||||||||||
Medical condition: Squamous cell non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005170-10 | Sponsor Protocol Number: COMBI-TED | Start Date*: 2021-04-30 | |||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | |||||||||||||
Full Title: A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progr... | |||||||||||||
Medical condition: metastatic non-small-cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004515-45 | Sponsor Protocol Number: GECP18/02 | Start Date*: 2019-04-02 | |||||||||||
Sponsor Name:Fundación GECP | |||||||||||||
Full Title: A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemotherapy alone for the treatment of locally advanced and potentially resectable non-small cell lung cancer (NSCLC) patients | |||||||||||||
Medical condition: Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003719-23 | Sponsor Protocol Number: CA209-9TN | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention with Adjuvant Nivolumab in Non- Small Cell Lung Cancer Participants with ctDNA detected Minimal Residual Disease after Surgical ... | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer with ctDNA detected Minimal Residual Disease after Surgical Resection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003668-32 | Sponsor Protocol Number: 2019-BN-001 | Start Date*: 2019-12-18 | ||||||||||||||||||||||||||
Sponsor Name:UZ Brussel | ||||||||||||||||||||||||||||
Full Title: A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myeloid dendritic cells in NSCLC | ||||||||||||||||||||||||||||
Medical condition: Oligometastatic solid tumors. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001994-25 | Sponsor Protocol Number: TACTI-002(IMP321P015);KeynotePN798 | Start Date*: 2019-02-12 | ||||||||||||||||||||||||||
Sponsor Name:Immutep S.A.S. | ||||||||||||||||||||||||||||
Full Title: TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurren... | ||||||||||||||||||||||||||||
Medical condition: Previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or recurrent or metastatic squamous head and neck cancer (HNSCC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
